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Introduction:
It is estimated that 15-25% of all human breast cancers are ER+/PR-with more aggressive malignant characteristics and poorer response to SERMs compared to ER+/PR+ breast cancers (1-3). However, the molecular mechanism underlying development of ER+/PR-breast cancers still remains elusive (1). Our data indicates that deletion of Tip30, a tumor suppressor, leads to development of ER+/PR-in MMTVNeu mouse model. The objective of this research project is to determine the molecular basis of ER+/PRbreast tumor development promoted by Tip30 deletion. Our rationale for these studies is that elucidation of molecular basis of ER+/PR-breast tumor development has the potential to identify new therapeutic targets and strategies in the treatment, or even prevention, of breast cancers that are resistant to antiestrogen therapy (2, 4) . Specifically, we will determine genetic and epigenetic alterations in the initiation and progression of ER+/PR-mammary tumors arising in Tip30-/-/MMTV-Neu mice; and we will also evaluate IGF-I and Wisp-2 as potential therapeutic targets for ER+/PR-mammary tumors developed in Tip30-/-MMTV-Neu mice.
Body:
Task 1. Determine specific genetic and epigenetic alterations in the initiation and progression of ER+/PR-mammary tumors arising in Tip30-/-/MMTV-Neu and Tip30+/-/MMTV-Neu mice. The experiments proposed in Task 1a, b, and c were completed in year one. In response to the last review comments on the supporting data for gene expression, we report here that the genes are involved in ion and protein transportation, cell adhesion, cell proliferation and apoptosis signaling pathways (Appendix Table) . Ingenuity pathway analysis of altered gene profiles revealed that cancer-associated pathways including EGF, IGF-I and PI3K/AKT signaling pathways were affected by Tip30 deletion in Neu+ mammary tumors. These results indicate that besides increasing IGF-I signaling, enhancing other growth factor signaling pathways such as EGF signaling in mammary epithelial cells could also contribute to the development of ER+/PR-mammary tumors.
Deletion of Tip30 leads to progressively increased numbers of p-Akt positive cells in the mammary glands from MMTV-Neu mice. The observation of increases in both EGF and IGF-I signaling pathways after deleting Tip30 led us to propose that PI3K/Akt and ERα are better targets for developing therapeutic strategies to inhibit ER+/PR-breast cancers. This is because both IGF-1 and EGF could activate PI3K/Akt, leading to phosphorylation of ERα (Fig. 3A and B) .
To determine whether Tip30 deletion can block EGFR trafficking from early endosomes to lysosomes for degradation, we tracked Alexa-488 conjugated EGF (Alexa 488 -EGF) and EGFR in normal primary MECs isolated from Tip30 -/-and Tip30 +/+ mice. The majority of internalized EGF dissociated from EGFR in wild type MECs two hours after EGF internalization. In contrast, they remained associated with EGFR in 
Tip30 -/-MECs (EGF-EGFR colocalization in wild type primary MECs: 11%; EGF-EGFR colocalization in

Tip30
-/-primary MECs: 55%; n = 20, P = 0.004; Fig. 3C and D -/-cells is indicative of delayed endocytic degradation of EGFR; the nucleus was stained with DAPI (Grey). Scale bar, 10 μm. D, Quantitative analysis of EGF and EGFR colocalization. Twenty cells in each group were analyzed using MBF_imageJ. Pearson's colocalization coefficients were calculated and converted to percentages. P = 0.035; t test.
Task 2. Evaluate IGF-I and Wisp-2 as potential therapeutic targets for ER+/PR-mammary tumors developed in
Tip30-/-MMTV-Neu mice. We have carried the experiments proposed in Task 2 in the second year. The preliminary findings led us to propose that PI3K is a better therapeutic for ER+/PRmammary tumors. 3 cells/well in DMEM, in the presence of saline or trastuzumab (50 μg/ml). Proliferation was analyzed using Cell Counting Kit-8 assay (Dojindo, Kumamoto, Japan) at indicated time points and absorbance at 485 nm was measured. The statistical significance was determined by using t test. C, Western blotting analysis of SKBr3 cells with control shRNA or TIP30-shRNAs. TIP30-shRNAs and control shRNA were purchased from Sigma-Aldrich Co. Preparation of shRNA lentiviruses and infection to SKBr3 cells was done according to manufacture's protocols.
AG1024, an IGF-IR inhibitor, can not effectively inhibit ER+/PR-mammary tumors developed in
A combination of NVP-BEZ235 and tamaxifen has a better inhibitory effect on proliferation of ER+/PR-mammary tumor cells compared to the use of either NVP-BEZ235 or tamoxifen alone.
Because the activation PI3K/Akt pathway is linked to multiple growth factors including IGF-I and EGF, PI3K would be an ideal candidate for combination therapies against ER+/PR-tumors. NVP-BEZ235 is a dual PI3K/mTOR inhibitor and effectively blocks phosphorylation of Akt and induces apoptosis of breast cancer cells having either HER2 amplification and/or PIK3CA mutation (10) . Thus, we tested whether NVP-BEZ235 alone or in combination with tamoxifen affects proliferation of ER+/PR-tumor cells. Simultaneous treatment of ER+/PR-tumor cells with NVP-BEZ235 and tamoxifen robustly inhibits cell proliferation in vitro, whereas NVP-BEZ235 or tamoxifen alone treatment has only moderate or no inhibition of proliferation of the cells in vitro ( Figure 6 ). These results suggest that a combined NVP-BEZ235 and tamoxifen treatment is a potentially effective strategy for treatment of ER+/PR-breast cancers. Tumor cells were seeded in 96-well plates in DMEM, in the presence of DMSO, tamoxifen (1 μm), NVP-BEZ235 (250 nM) or tamoxifen (1 μm) plus NVP-BEZ235 (250 nM) at 0 hr. Proliferation was analyzed using Cell Counting Kit-8 assay (Dojindo, Kumamoto, Japan) at indicated time points and absorbance at 485 nm was measured. The statistical significance was determined by using t test.Data are mean ± SE from three experiments. Statistical significance was analyzed by a t-test (*P < 0.05; NVP-BEZ235 treatment versus control vehicle treatment; **P < 0.05; NVP-BEZ235 and tamoxifen treatment versus control vehicle treatment). 
